Loading viewer...
investor_presentation
Format: PDF investor_presentation
Verona Pharma plc presents ensifentrine, a Phase 3 first-in-class inhaled dual PDE3/PDE4 inhibitor for maintenance treatment of COPD. The presentation highlights positive ENHANCE-2 clinical data, a large ~$10B US market opportunity, and significant unmet need among symptomatic patients despite existing dual/triple therapies.
investor_presentation
27 Pages
investor_presentation
47 Pages
Embark Trucks, Inc.
Hanmi Financial 1Q24 Investor Presentation 2024
investor_presentationinvestor_presentation
48 Pages
Hanmi Financial Corporation
Aberdeen European Residential Opportunities Fund Bond Amendment 2024
investor_presentationinvestor_presentation
24 Pages
Aberdeen European Residential Opportunities Fund